Baseline demographic and disease-related patient characteristics
| Characteristic . | Bor-HDM (n = 154) . | HDM (n = 146) . |
|---|---|---|
| Sex, Male/Female, n | 99/55 | 83/63 |
| Age, median (Q1-Q3), y | 58 (52-63) | 58 (52-62) |
| Isotype, n (%) | ||
| IgG | 93 (60.4) | 98 (67.1) |
| IgA | 38 (24.7) | 31 (21.2) |
| Light chain/others | 21/2 (13.6/1.3) | 16/1 (11.0/0.7) |
| ISS stage, n (%) | ||
| I, II | 89/43 (85.7) | 80/45 (85.6) |
| III | 22 (14.3) | 21 (14.4) |
| β2-Microglobulin, median (Q1-Q3), mg/L | 2.82 (2.15-4.30) | 3.00 (2.32-4.10) |
| Albumin, median (Q1-Q3), g/L | 40.9 (36.7-44.3) | 40.7 (36.8-44.1) |
| “CRAB” criterion, n (%) | ||
| Calcium elevation | 8 (5.2) | 8 (5.5) |
| Renal insufficiency | 2 (1.3) | 6 (4.1) |
| Anemia | 45 (29.2) | 44 (30.1) |
| Bone lesions | 129 (83.8) | 134 (91.8) |
| Cytogenetic risk, n/N (%) | ||
| Standard risk | 109/151 (72.2) | 106/144 (73.6) |
| High risk [del(17p) and/or t(4;14)] | 25/151 (16.6) | 22/144 (15.3) |
| Non-informative | 17/151 (11.3) | 16/144 (11.1) |
| del(17p) | 7/133 (5.3) | 10/128 (7.8) |
| t(4;14) | 18/136 (13.2) | 13/129 (10.1) |
| Frontline treatments, n (%) | ||
| VTd | 137 (89.0) | 125 (85.6) |
| VCD/CyBorD | 16 (10) | 18 (12.3) |
| Response after induction, n (%) | ||
| At least very good partial response | 90 (58.4) | 83 (56.8) |
| Partial response or stable disease | 64 (41.6) | 63 (43.2) |
| Characteristic . | Bor-HDM (n = 154) . | HDM (n = 146) . |
|---|---|---|
| Sex, Male/Female, n | 99/55 | 83/63 |
| Age, median (Q1-Q3), y | 58 (52-63) | 58 (52-62) |
| Isotype, n (%) | ||
| IgG | 93 (60.4) | 98 (67.1) |
| IgA | 38 (24.7) | 31 (21.2) |
| Light chain/others | 21/2 (13.6/1.3) | 16/1 (11.0/0.7) |
| ISS stage, n (%) | ||
| I, II | 89/43 (85.7) | 80/45 (85.6) |
| III | 22 (14.3) | 21 (14.4) |
| β2-Microglobulin, median (Q1-Q3), mg/L | 2.82 (2.15-4.30) | 3.00 (2.32-4.10) |
| Albumin, median (Q1-Q3), g/L | 40.9 (36.7-44.3) | 40.7 (36.8-44.1) |
| “CRAB” criterion, n (%) | ||
| Calcium elevation | 8 (5.2) | 8 (5.5) |
| Renal insufficiency | 2 (1.3) | 6 (4.1) |
| Anemia | 45 (29.2) | 44 (30.1) |
| Bone lesions | 129 (83.8) | 134 (91.8) |
| Cytogenetic risk, n/N (%) | ||
| Standard risk | 109/151 (72.2) | 106/144 (73.6) |
| High risk [del(17p) and/or t(4;14)] | 25/151 (16.6) | 22/144 (15.3) |
| Non-informative | 17/151 (11.3) | 16/144 (11.1) |
| del(17p) | 7/133 (5.3) | 10/128 (7.8) |
| t(4;14) | 18/136 (13.2) | 13/129 (10.1) |
| Frontline treatments, n (%) | ||
| VTd | 137 (89.0) | 125 (85.6) |
| VCD/CyBorD | 16 (10) | 18 (12.3) |
| Response after induction, n (%) | ||
| At least very good partial response | 90 (58.4) | 83 (56.8) |
| Partial response or stable disease | 64 (41.6) | 63 (43.2) |
ISS, International Staging System; Ig, immunoglobulin; VCD/CyBorD, bortezomib, cyclophosphamide and dexamethasone.